Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBIT Margin (2021 - 2025)

Krystal Biotech's EBIT Margin history spans 4 years, with the latest figure at 41.34% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 409.0% year-over-year to 41.34%; the TTM value through Dec 2025 reached 41.45%, up 1882.0%, while the annual FY2025 figure was 41.45%, 1882.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 41.34% at Krystal Biotech, down from 42.48% in the prior quarter.
  • Across five years, EBIT Margin topped out at 962.0% in Q1 2021 and bottomed at 303.8% in Q3 2023.
  • The 4-year median for EBIT Margin is 40.94% (2025), against an average of 81.94%.
  • The largest annual shift saw EBIT Margin soared 33060bps in 2024 before it crashed -409bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 962.0% in 2021, then tumbled by -99bps to 7.7% in 2023, then skyrocketed by 490bps to 45.43% in 2024, then decreased by -9bps to 41.34% in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBIT Margin are 41.34% (Q4 2025), 42.48% (Q3 2025), and 40.94% (Q2 2025).